成人急性淋巴细胞白血病治疗进展
Progress in treatment of adult acute lymphoblastic leukemia
刘文慧 1吴涛 1张曦2
作者信息
- 1. 中国人民解放军联勤保障部队第九四〇医院血液科,甘肃 兰州 730050
- 2. 中国人民解放军陆军军医大学第二附属医院血液科,重庆 400037
- 折叠
摘要
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是以原始幼稚淋巴细胞异常增殖并抑制正常造血的血液系统恶性肿瘤,起源于B系或T系淋巴祖细胞,占成人急性白血病的20%～30%.虽然初诊成人ALL患者在多药联合化疗后完全缓解率可达80%以上,但仍有大部分患者最终出现复发、难治,5年长期生存率仅20%～40%,其临床特点及预后差异较大.近年来,随着靶向药物、免疫治疗、嵌合抗原受体(chimeric antigen receptor,CAR)-T细胞疗法等问世,极大地改善了成人ALL患者的临床结局.本文详细综述目前成人ALL新型治疗药物的进展.
Abstract
Acute lymphoblastic leukemia(ALL)is a hematological malignancy with abnormal proliferation of primitive naive lymphocytes and inhibition of normal hematopoiesis.It originates from B-lineage or T-lineage lymphoid progenitor cells,accounting for 20%-30%of adult acute leukemia.Although the complete remission rate of newly diagnosed adult ALL patients after multi-drug combination chemotherapy can reach more than 80%,most of the patients still show relapse and refractory.The 5-year long term survival rate in the patients is only 20%-40%and the clinical characteristics and prognosis are quite different.In recent years,with the advent of targeted drugs,immunotherapy,and chimeric antigen receptor(CAR)-T cell therapy,the clinical outcomes of adult ALL patients have been greatly improved.This article reviews the current progress of new therapeutic drugs for adult ALL in detail.
关键词
急性淋巴细胞白血病/酪氨酸激酶抑制剂/兰妥莫单抗/伊组单抗奥加米星/嵌合抗原受体T细胞/Venetoclax/奈拉滨Key words
Acute lymphoblastic leukemia/Tyrosine kinase inhibitors/Blinatumomab/Inotuzumab ozogamicin/Chimeric antigen receptor T cell/Venetoclax/Nelarabine引用本文复制引用
基金项目
甘肃省科技计划(创新基地和人才计划)项目(21JR7RA015)
甘肃省科技计划项目(22YF7FA106)
联勤保障部队第九四〇医院科研项目(2021yxky078)
出版年
2024
国家科技期刊平台
NSTL
万方数据